Erratum: MicroRNA‑24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3 (Int J Oncol (2015) 47 (1351-1360) DOI: 10.3892/ijo.2015.3117);MicroRNA-24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3

International Journal of Oncology

Volumn 47, Issue 4, 2015, Pages 1351-1360

  Zhang, Shufang ^a   Zhang, Chong ^a   Liu, Wei ^b   Zheng, Wenwen ^a   Zhang, Yingai ^a   Wang, Shunlan ^a   Huang, Denggao ^a   Liu, Xi ^a   Bai, Zhiming ^a  

^a Central South University   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; CARMA3; Epithelial to mesenchymal transition; Invasion; MiR 24; Proliferation

Indexed keywords

CARMA3 PROTEIN; MICRORNA 24; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; CARD10 PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; MICRORNA; MIRN24 MICRORNA, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BIOINFORMATICS; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE TARGETING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; METASTASIS; PRIORITY JOURNAL; UPREGULATION; BIOSYNTHESIS; BLADDER TUMOR; CELL CYCLE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CARD SIGNALING ADAPTOR PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84940973765     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2023.5515     Document Type: Erratum

References (45)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25: 219-278, 2001.
3. Bulbul MA, Husseini N and Houjaij A: Superficial bladder cancer epidemiology, diagnosis and management. J Med Liban 53: 107-113, 2005.
4. Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response to bacillus Calmette Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61: 128-145, 2012.
5. V inall RL, Ripoll AZ, Wang S, Pan CX and deVere White RW: MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130: 2526-2538, 2012.
6. Luke C, Tracey E, Stapleton A and Roder D: Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for research and cancer control. Intern Med J 40: 357-362, 2010.
7. Jiang QQ, Liu B and Yuan T: MicroRNA-16 inhibits bladder cancer proliferation by targeting Cyclin D1. Asian Pac J Cancer Prev 14: 4127-4130, 2013.
8. Bellmunt J and Petrylak DP: New therapeutic challenges in advanced bladder cancer. Semin Oncol 39: 598-607, 2012.
9. Bartel DP: Micrornas: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
10. Kim VN, Han J and Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139, 2009.
11. Thomson DW, Bracken CP and Goodall GJ: Experimental strategies for microRNA target identification. Nucleic Acids Res 39: 6845-6853, 2011.
12. Wiemer EA: The role ofmicroRNAs in cancer: no small matter. Eur J Cancer 43: 1529-1544, 2007.
13. Andrew AS, Marsit CJ, Schned AR, Seigne JD, Kelsey KT, Moore JH, Perreard L, Karagas MR and Sempere LF: Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. Int J Cancer: Dec 29, 2014 (Epub ahead of print). doi: 10.1002/ijc.29413.
14. Zhang T, Wang J, Zhai X, Li H, Li C and Chang J: MiR-124 retards bladder cancer growth by directly targeting CDK4. Acta Biochim Biophys Sin (Shanghai). 46: 1072-1079, 2014.
15. Wang X, Wu J, Lin Y, Zhu Y, Xu X, Xu X, Liang Z, Li S, Hu Z, Zheng X and Xie L: MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6. J Exp Clin Cancer Res 33: 69, 2014.
16. Zeng T, Peng L, Chao C, Fu B, Wang G, Wang Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol 7: 7653-7662, 2014.
17. Liang Z, Li S, Xu X, Xu X, Wang X, Wu J, Zhu Y, Hu Z, Lin Y, Mao Y, et al: MicroRNA-576-3p inhibits proliferation in bladder cancer cells by targeting cyclin D1. Mol Cells 38: 130-137, 2015.
18. Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P and Yu Z: miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res 33: 67, 2014.
19. Xiu Y, Liu Z, Xia S, Jin C, Yin H, Zhao W and Wu Q: MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3. PLoS One 9: e109734, 2014.
20. Zhang DQ, Zhou CK, Jiang XW, Chen J and Shi BK: Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol 12: 241, 2014.
21. Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, Yu Y, Li C, Su L, Zhu Z, Xiang M, Liu B and Yang Q: Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. Mol Cancer 13: 127, 2014.
22. Song L, Yang J, Duan P, Xu J, Luo X, Luo F, Zhang Z, Hou T, Liu B and Zhou Q: MicroRNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting LPAATβ. Arch Biochem Biophys 535: 128-135, 2013.
23. Yin JY, Deng ZQ, Liu FQ, Qian J, Lin J, Tang Q, Wen XM, Zhou JD, Zhang YY and Zhu XW: Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer. Int J Clin Exp Pathol 7: 4261-4267, 2014.
24. Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, Wang C, Xing TY and Xia Q: MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int 2014: 482926, 2014.
25. Blonska M and Lin X: NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 21: 55-70, 2010.
26. Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, Manji GA, Merriam S, Glucksmann MA, DiStefano PS, Alnemri ES and Bertin J: Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. J Biol Chem 276: 21405-21409, 2001.
27. Banan A, Zhang LJ, Farhadi A, Fields JZ, Shaikh M and Keshavarzian A: PKC-beta1 isoform activation is required for EGF-induced NF-kappaB inactivation and IkappaBalpha stabilization and protection of F-actin assembly and barrier function in enterocytemonolayers. Am J Physiol Cell Physiol 286: C723-C738, 2004.
28. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nuñez G and Lucas PC: CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 104: 139-144, 2007.
29. Grabiner BC, Blonska M, Lin PC, You Y, Wang D, Sun J, Darnay BG, Dong C and Lin X: CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-κB activation. Genes Dev 21: 984-996, 2007.
30. Wang D, You Y, Lin PC, Xue L, Morris SW, Zeng H, Wen R and Lin X: Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA 104: 145-150, 2007.
31. Wu GL, Yuan JL, Huang XD, Rong JF, Zhang LX, Liu YP and Wang FL: Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma. Tumour Biol 34: 3431-3435, 2013.
32. Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X, You Y and Li J: CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-kappaB regulation in breast cancer cells. Tumour Biol 34: 3041-3047, 2013.
33. Miao Z, Zhao T, Wang Z, Xu Y, Song Y, Wu J and Xu H: CARMA3 is overexpressed in colon cancer and regulates NF-kappaB activity and cyclin D1 expression. Biochem Biophys Res Commun 425: 781-787, 2012.
34. Man X, He J, Kong C, Zhu Y and Zhang Z: Clinical significance and biological roles of CARMA3 in human bladder carcinoma. Tumour Biol 35: 4131-4136, 2014.
35. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC and Lin X: CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res 71: 2183-2192, 2011.
36. Borthakur A, Bhattacharyya S, Alrefai WA, Tobacman JK, Ramaswamy K and Dudeja PK: Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. Inflamm Bowel Dis 16: 593-603, 2010.
37. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5771, 2010.
38. Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 34: 2093-2098, 2013.
39. Yin J, Lin J, Luo X, Chen Y, Li Z, Ma G and Li K: miR-137: a new player in schizophrenia. Int J Mol Sci 15: 3262-3271, 2014.
40. V ogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004.
41. Nevins JR: The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703, 2001.
42. Yao Q, Chen J, Lv Y, Wang T, Zhang J, Fan J and Wang L: The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues. Tumour Biol 32: 1163-1171, 2011.
43. Korbakis D and Scorilas A: Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol 33: 865-875, 2012.
44. Li Z, Qu L, Dong Q, Huang B, Li H, Tang Z, Xu Y, Luo W, Liu L, Qiu X and Wang E: Overexpression of CARMA3 in non-smallcell lung cancer is linked for tumor progression. PLoS One 7: e36903, 2012.
45. Du S, Jia L, Zhang Y, Fang L, Zhang X and Fan Y: CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion. Tumour Biol 35: 5965-5970, 2014.